Therapeutic Apheresis Services
Therapeutic Apheresis Services (TAS) provide life-saving and life-enhancing therapeutic apheresis services to adults and children. Patients are either treated in an NHS Blood and Transplant (NHSBT) unit or, when clinically appropriate, hospital.
For more information read our service portfolio.
TAS services are delivered across England and North Wales from eight therapeutic apheresis units. To make a patient referral or discuss services please contact your local TAS unit.
TAS is managed by Catherine Howell, Chief Nurse, who is supported by a management team of Dr James Griffin, Clinical Director; Davina Potok, Nursing Lead: Care Quality, Regulation and Governance; Kay Harding, Senior Nurse Manager; Elaine Howe, Therapeutic Apheresis Lead for London; Lydia Ball, Business Support Manager, and Olivia Pirret, National Administrator.
TAS supports a range of clinical specialties including haematology, oncology, nephrology, neurology and rheumatology. Therapeutic procedures include:
- Peripheral Blood Stem Cell Collection (PBSC)
Collection of peripheral blood stem cells from either patients or donors, which are used for transplantation. Transplantation is usually required following high dose chemotherapy which destroys a patient’s bone marrow.
- Lymphocyte Collection (DLI)
Collection of lymphocyte white cells from donors who have previously donated bone marrow or peripheral blood stem cells.
- Therapeutic Plasma Exchange (TPE)
Removal of disease mediators, excessive/abnormal constituents from plasma or replacement of deficient constituents.
- Red Cell Exchange (RCE)
Removal and replacement of a patient’s red blood cells.
- Platelet Depletion
Removal of platelets in patients with very high platelet counts due to disease.
- White Cell Depletion
Removal of white cells in patients with very high white cell counts due to disease.
- Low Density Lipid Removal (LDL)
Removal of LDL cholesterol molecules using filtration technology.
- Extracorporeal Photopheresis (ECP)
An integrated two-stage procedure in which white cells are collected, removed then treated with a photo activated drug and exposed to ultraviolet light before being returned to the patient.
End of Year Review
At the end of each financial year TAS completes a review of its key achievements and priorities for the year ahead. The end of year review summary is distributed to users of TAS services for their information and interest.
Our newsletters give an overview of the key initiatives we are undertaking to improve patient access to services and treatment provision across England. Each issue focuses on a clinical speciality.
- Issue 1 - February 2018
Supporting Sickle Cell Disease patients